180300-61-2

Upstream product

• 211113-55-2 1,2,3,5-tetra-O-benzoyl-3-C-ethenyl-α,β-D-ribo-pentofuranose 
• 180300-90-7 ((3aR,5R,6R,6aR)-6-hydroxy-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl benzoate 
• 103931-45-9 5-O-(tert-butyldimethylsilyl)-1,2-O-isopropylidene-α-D-erythro-pentofuranos-3-ulose 
• 180300-67-8 1-(2,3,5-tri-O-benzoyl-3-C-ethenyl-β-D-ribofuranosyl)uracil 
• 180300-89-4 5-O-tert-butyldimethylsilyl-1,2-O-isopropylidene-3-C-ethenyl-α-D-ribofuranose 
• 221227-58-3 (3aR,5R,6R,6aR)-5-(hydroxymethyl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 

Relevant academic research and scientific papers

Nucleosides and nucleotides, 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3- C-ethynyl-β-d-ribo-pentofuranosyl)cytosine and -uracil

We previously designed 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil (EUrd) and its cytosine congener (ECyd) as potential multifunctional antitumor nucleoside antimetabolites. They showed potent and broad-spectrum antitumor activity against various human

3'-substituted nucleoside derivatives

The invention relates to a 3'-substituted nucleoside derivative represented by the following general formula (1): STR1 wherein B means a nucleic acid base which may have a substituent, Z represents a lower alkynyl or lower alkenyl group which may be subst